TY - JOUR
T1 - Emerging immunomodulatory strategies for cell therapeutics
AU - Chua, Corrine Ying Xuan
AU - Jiang, Allen Yujie
AU - Eufrásio-da-Silva, Tatiane
AU - Dolatshahi-Pirouz, Alireza
AU - Langer, Robert
AU - Orive, Gorka
AU - Grattoni, Alessandro
N1 - Funding Information:
We received funding support from National Institutes of Health (NIH) grant R01DK132104 (A.G.), Juvenile Diabetes Research Foundation (JDRF) [ 2-SRA-2022-1224-S-B (A.G.); 2-SRA-2021-1078-S-B (A.G.)], Vivian L. Smith Foundation (A.G. and C.Y.X.C.), and Men of Distinction Foundation (A.G. and C.Y.X.C.). A.Y.J. is supported by a NIH grant 4UH3HL147367-04 . This work was also supported by the Spanish Ministry of Economy, Industry, and Competitiveness ( PID2019-106094RB-I00/AEI/10.13039/501100011033 ). The authors wish to thank the graphic designer Virginia Facciotto ( virginia.facciotto@gmail.com ) for the figure preparations.
Funding Information:
We received funding support from National Institutes of Health (NIH) grant R01DK132104 (A.G.), Juvenile Diabetes Research Foundation (JDRF) [2-SRA-2022-1224-S-B (A.G.); 2-SRA-2021-1078-S-B (A.G.)], Vivian L. Smith Foundation (A.G. and C.Y.X.C.), and Men of Distinction Foundation (A.G. and C.Y.X.C.). A.Y.J. is supported by a NIH grant 4UH3HL147367-04. This work was also supported by the Spanish Ministry of Economy, Industry, and Competitiveness (PID2019-106094RB-I00/AEI/10.13039/501100011033). The authors wish to thank the graphic designer Virginia Facciotto (virginia.facciotto@gmail.com) for the figure preparations. No interests are declared.
Publisher Copyright:
© 2022 The Author(s)
PY - 2023/3
Y1 - 2023/3
N2 - Cellular therapies are poised to transform the field of medicine by restoring dysfunctional tissues and treating various diseases in a dynamic manner not achievable by conventional pharmaceutics. Spanning various therapeutic areas inclusive of cancer, regenerative medicine, and immune disorders, cellular therapies comprise stem or non-stem cells derived from various sources. Despite numerous clinical approvals or trials underway, the host immune response presents a critical impediment to the widespread adoption and success of cellular therapies. Here, we review current research and clinical advances in immunomodulatory strategies to mitigate immune rejection or promote immune tolerance to cellular therapies. We discuss the potential of these immunomodulatory interventions to accelerate translation or maximize the prospects of improving therapeutic outcomes of cellular therapies for clinical success.
AB - Cellular therapies are poised to transform the field of medicine by restoring dysfunctional tissues and treating various diseases in a dynamic manner not achievable by conventional pharmaceutics. Spanning various therapeutic areas inclusive of cancer, regenerative medicine, and immune disorders, cellular therapies comprise stem or non-stem cells derived from various sources. Despite numerous clinical approvals or trials underway, the host immune response presents a critical impediment to the widespread adoption and success of cellular therapies. Here, we review current research and clinical advances in immunomodulatory strategies to mitigate immune rejection or promote immune tolerance to cellular therapies. We discuss the potential of these immunomodulatory interventions to accelerate translation or maximize the prospects of improving therapeutic outcomes of cellular therapies for clinical success.
KW - cell transplantation
KW - cellular therapy
KW - immune modulation
KW - immunosuppression
UR - http://www.scopus.com/inward/record.url?scp=85144777524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144777524&partnerID=8YFLogxK
U2 - 10.1016/j.tibtech.2022.11.008
DO - 10.1016/j.tibtech.2022.11.008
M3 - Review article
C2 - 36549959
SN - 0167-7799
VL - 41
SP - 358
EP - 373
JO - Trends in Biotechnology
JF - Trends in Biotechnology
IS - 3
ER -